Consumers anxious about drug costs, industry influence

Share this article:
A fifth of consumers have asked their doctor to prescribe a drug they learned about through advertising, and fully two-thirds have received free samples of prescription drugs from their doctor – but they worry about the industry's influence on physicians, according to a Consumer Reports survey.

The phone survey of 1,154 US adults who currently take prescription drugs posed assertions about industry bias of physician prescribing, and found nine in 10 in agreement with at least one, including statements that: "companies have too much influence on the drugs doctors prescribe" (69%); docs "are too eager to prescribe a drug rather than consider alternate methods of managing a condition" (50%); docs "are influenced by gifts" from pharmas (47%); and "tend to prescribe newer, more expensive drugs" (41%). When respondents were quizzed about their concern over a list of industry marketing practices, some dubious, 81% said they worried about companies rewarding docs for writing a lot of prescriptions for their products.

Other unpopular practices included “paying docs to provide testimonials or serve as spokespersons for a drug" (72%), “Paying doctors to speak at industry conferences" (61%), “Buying meals for the doctor and their staff" (58%) and "providing free samples of their drugs" to docs (41%)? Not so concerned that they wouldn't take a sample themselves, apparently.

Leading questions about industry bias aside, the survey revealed widespread concerns about drug costs and an alarming rate of non-compliance, largely due to affordability issues. Four in 10 reported taking some action to reduce costs, and more than a quarter (27%) said they'd failed to take a drug as prescribed, whether by not filling a prescription (16%), taking an expired medication (12%) or sharing a prescription with someone else to save money (4%).
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...